How do I get infliximab through my insurance?
Compare IV infliximab products · product preference · authorization · billing · site of care
No account, member ID, name, date of birth or email is needed. Your selections stay in this page session.
Which infliximab product are you trying to get?
FDA’s Purple Book lists Remicade as the reference product and Inflectra, Avsola and Renflexis as biosimilars to Remicade. FDA explains that an approved biosimilar is highly similar to its reference product, with no clinically meaningful differences in safety, purity and potency. Insurance coverage can still be product-specific.
Find out what is holding up the request.
Ask for the exact reason for any denial and the policy or criteria used. A medical-necessity decision is different from a preferred-product rule.
A plan may apply product-specific coverage rules. Confirm the brand or suffix on the prescription, authorization and approval instead of relying on the word “infliximab” alone.
An approved medicine can still be delayed when the requested hospital, clinic or infusion site does not match the authorization or network rule.
Compare the product, billing code (HCPCS), units, service date, treatment location and authorization. A claim problem is not automatically a new clinical denial.
- the exact product name and the four-letter ending after “infliximab,” if present;
- whether the request is for an IV infusion or a subcutaneous product;
- the diagnosis, treatment site and requested date range;
- the product and site named on the authorization;
- the denial or claim code and the exact reason stated by the plan.
Zymfentra follows a separate subcutaneous path. FDA lists Zymfentra as a subcutaneous infliximab-dyyb product approved under the 351(a) pathway. Its prescribing information describes maintenance treatment for adults with moderately to severely active ulcerative colitis or Crohn’s disease after IV infliximab induction. This guide focuses on the four IV products and does not assume how an individual plan assigns the benefit.
Check the coverage path for the exact product.
Choose the diagnosis and coverage type. The tool keeps the selected IV product visible and points to the official plan source when one is available.
Choose the diagnosis / reason.
The same infliximab product family can have very different medical-necessity requirements by diagnosis.
Make sure the prescription, authorization and infusion match.
If a preferred product is named
Ask the prescriber and infusion site whether the prescription, authorization and planned claim all name that same product. Do not change products based on this guide alone.
If the reason is unclear
Ask whether the block is medical necessity, product preference, site of care or a claim mismatch. Each problem has a different next step.
Find help with your out-of-pocket costs.
Use the official support program below to check savings, patient-assistance, or access options that may apply to you.
J&J withMe — Infliximab →What to clarify before treatment or an appeal.
Does approval for “infliximab” approve every infliximab product?
Do not assume it does. Ask the plan or authorization department which exact product, HCPCS code, site and date range were approved, then compare that answer with the prescription and planned infusion.
What if the plan prefers a different product?
Ask for the current product-preference rule and what the plan requires for the requested product. The prescriber and plan should decide whether an exception request or a revised authorization is appropriate.
Why does the billing code matter?
CMS lists J1745 for infliximab excluding biosimilars, Q5103 for Inflectra, Q5104 for Renflexis and Q5121 for Avsola, each per 10 mg. The treatment site should verify current payer and CMS coding for the product actually administered.
How is Zymfentra different?
FDA lists Zymfentra as a distinct subcutaneous infliximab-dyyb product. This guide compares the four provider-administered IV products, so Zymfentra’s route and maintenance pathway require separate coverage questions.
The medicine may be only part of the problem.
Use the playbook that matches what is blocking treatment, then verify the current rule with the insurer, program or treatment site.
Approval is pending, expired or unclear.
Find the rule, status and next authorization step.
DENIEDFind the reason before appealing.
Separate medical-necessity, benefit, product and claim problems.
PREFERRED PRODUCTThe plan wants a different brand or biosimilar.
Understand product preference without making a treatment recommendation.
SITE OF CAREThe medicine may be covered, but the location is not.
Check network, site and authorization requirements.
COST TOO HIGHSeparate coverage from financial assistance.
Understand manufacturer support versus independent foundations.
CLAIM PROBLEMAuthorization was approved, but billing still failed.
Compare the approval with the product, site and claim that were billed.
Important
MedicineCostHelp is an educational navigation tool, not an insurer and not a coverage determination. The member’s benefit plan, medical necessity, prior authorization, product preference, current billing code and site-of-care rules can change the outcome. Sources were reviewed 2026-10-08. Verify the current official source before acting.